Heightened surveillance of acute febrile illness in China since 2009 has led to the identification of a severe fever with thrombocytopenia syndrome (SFTS).
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
In late March, 2011 ECDC reported that the Swedish Medical Product Agency published preliminary results from an on-going cohort study involving 5.3 million people, where 67% of children and adolescents and 51.0% of adults were vaccinated with Pandemrix.
ECDC and WHO Europe jointly release “MESSAGE - MEaSles and rubella Self Assessment GEnerating tool” for public health experts, to facilitate assessment of the progress made towards measles and rubella elimination.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
Tick-borne zoonoses (TBZ) are emerging diseases worldwide. A large amount of information (e.g. case reports, results of epidemiological surveillance, etc.) is dispersed through various reference sources (ISI and non-ISI journals, conference proceedings, technical reports, etc.).